Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging
|ClinicalTrials.gov Identifier: NCT01745874|
Recruitment Status : Unknown
Verified December 2012 by Milena Cerny, University of Lausanne Hospitals.
Recruitment status was: Recruiting
First Posted : December 10, 2012
Last Update Posted : December 10, 2012
|Condition or disease|
Rectal cancer is the second cause of mortality after lung cancer in industrialized countries and represent 28% of colorectal carcinomas. Despite major improvements in diagnosis and treatment made those last years,mortality and morbidity remains high, because of high prevalence of metastasis and local recurrence. A accurate initial staging is of paramount importance for an appropriate treatment (neoadjuvant chemiotherapy and radiotherapy, surgery).
Actually, there is no international consensus concerning imaging for the staging of rectal cancer and modalities used are variable from one center to another.
WB-MRI represented a attractive and promising technique for the staging of rectal cancer, free of ionizing radiation .
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Diagnostic Value of Whole-Body MRI Compared to FDG-PET-CT for Rectal Cancer Preoperative Staging, Before and After Neoadjuvant Treatment|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||October 2013|
- Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment [ Time Frame: baseline and 1 week before surgery ]We will compare for each body region the findings of the whole-body MRI to the FDG-PET-CT considered as the gold-standard and measure sensibility/specificity and diagnostic accuracy of the whole-body MRI for distant lesions of rectal cancer.
- Tumoral regression after neoadjuvant treatment [ Time Frame: baseline and six weeks after the end of the neoadjuvant treatment ]Evaluate the tumoral regression after neoadjuvant treatment on the MRI by the measurement of the ADC (attenuation diffusion coefficient) increase and compare the results to the measure of the SUV (standard uptake value) decrease on the FDG-PET-CT.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01745874
|University of Lausanne Hospitals||Recruiting|
|Lausanne, Vaud, Switzerland, 1011|
|Contact: Milena Cerny, Resident 0041795561102 email@example.com|
|Contact: Sabine Schmidt Kobbe, MER 0041213144444 firstname.lastname@example.org|
|Principal Investigator:||Milena Cerny||University of Lausanne Hospitals|
|Principal Investigator:||Sabine Schmidt Kobbe, Dr.||University of Lausanne Hospitals|